1. Home
  2. DSM vs NMRA Comparison

DSM vs NMRA Comparison

Compare DSM & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DSM
  • NMRA
  • Stock Information
  • Founded
  • DSM 1989
  • NMRA 2019
  • Country
  • DSM United States
  • NMRA United States
  • Employees
  • DSM N/A
  • NMRA N/A
  • Industry
  • DSM Investment Managers
  • NMRA
  • Sector
  • DSM Finance
  • NMRA
  • Exchange
  • DSM Nasdaq
  • NMRA Nasdaq
  • Market Cap
  • DSM 289.7M
  • NMRA 287.6M
  • IPO Year
  • DSM N/A
  • NMRA 2023
  • Fundamental
  • Price
  • DSM $5.80
  • NMRA $1.18
  • Analyst Decision
  • DSM
  • NMRA Buy
  • Analyst Count
  • DSM 0
  • NMRA 8
  • Target Price
  • DSM N/A
  • NMRA $10.14
  • AVG Volume (30 Days)
  • DSM 161.7K
  • NMRA 1.4M
  • Earning Date
  • DSM 01-01-0001
  • NMRA 03-03-2025
  • Dividend Yield
  • DSM 3.97%
  • NMRA N/A
  • EPS Growth
  • DSM N/A
  • NMRA N/A
  • EPS
  • DSM N/A
  • NMRA N/A
  • Revenue
  • DSM N/A
  • NMRA N/A
  • Revenue This Year
  • DSM N/A
  • NMRA N/A
  • Revenue Next Year
  • DSM N/A
  • NMRA N/A
  • P/E Ratio
  • DSM N/A
  • NMRA N/A
  • Revenue Growth
  • DSM N/A
  • NMRA N/A
  • 52 Week Low
  • DSM $4.69
  • NMRA $1.16
  • 52 Week High
  • DSM $6.05
  • NMRA $17.19
  • Technical
  • Relative Strength Index (RSI)
  • DSM 36.50
  • NMRA 28.48
  • Support Level
  • DSM $6.01
  • NMRA $1.26
  • Resistance Level
  • DSM $6.10
  • NMRA $1.48
  • Average True Range (ATR)
  • DSM 0.05
  • NMRA 0.13
  • MACD
  • DSM -0.02
  • NMRA 0.08
  • Stochastic Oscillator
  • DSM 9.27
  • NMRA 10.99

About DSM BNY Mellon Strategic Municipal Bond Fund Inc.

BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

Share on Social Networks: